Santersus AG Achieves Breakthrough in Lung Transplantation Research
October 22, 2024
Menu
News
Recent news
October 22, 2024
Santersus AG is proud to announce the successful publication of its latest research, “Restoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps”, in the prestigious Journal of Heart and Lung Transplantation. This innovative work offers a transformative solution to address the global shortage of viable lungs for transplantation, utilizing advanced ex vivo lung perfusion (EVLP) techniques to repair lungs previously deemed unusable.
September 26, 2024
Santersus AG has been recognized as a National Abstract Winner at the prestigious UK ECPR Summit, held at the Royal Society of Medicine on Monday, September 23rd 2024. The award highlights the company’s pioneering research on selective cell-free DNA/NETs apheresis with NucleoCapture, presented in a highly acclaimed poster at the critical care section of the event. This innovative approach offers promising advances in critical care treatment, reinforcing Santersus AG’s commitment to cutting-edge medical solutions.
July 30, 2024
In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) and Dr. Hussain Abbas (DPhil, Transplant Surgery, University of Oxford) represented Santersus AG in the 2024 International Congress of ILTS, held in Houston (Texas, USA).
In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ILTS 2023 Congress on Liver Transplantation, held in Rotterdam where he presented a Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine perfusion (NMP). The study concluded that NucleoCapture was able to effectively remove circulating nucleosomes/NETs from the perfusate during NMP, improving graft function and mitigating ERI.